Initially founded as a spin-off of Vidorreta Design, it was incorporated as a company in 2022, within the Vidorreta Design Group, Ysium Medical has already stood out for its advances in specialized devices in its four lines of research: Neurology, Oncology, Medical Simulation and Personalized Medicine. This round closing underlines the confidence of the investors in the potential of the company and its business model, laying the foundations for sustainable growth in the medical technology sector.

In this operation, the two co-founders, Zuriñe Aguirre CEO of the company and Javier Vidorreta, CTO, are joined by a varied group of investors who bring not only capital, but also a broad background and extensive experience in both business and the health sector, to greatly increase human capital and knowledge to achieve future successes. the human capital and knowledge of the company in order to achieve future successes. The operation has counted with the participation of Sodena, a public company dependent on the Government of Navarre, as the lead investor 200,000, the holding of the founders Vidorreta Design Group with 250,000, as well as several Business Angels, including Sixto Jiménez, Mariano Fernández Fairén, Julio Villalobos, the Family Office of the Zamarripa Family and members of the Network of Experts of the company, such as Joaquín Sevilla.

With the funds raised, the company will be able to to intensify its research, develop its internationalization strategy, expand its knowledge ecosystemThe company plans to expand its knowledge ecosystem and collaboration networks in order to broaden its project portfolio. In addition, it plans to expand its team and strengthen its operational capacity, with a view to facilitating the transfer of its innovative technologies to leading global multinationals.

It is worth noting the rapid growth of this young company, which in just two and a half years already has two patents and another two in the process of development, several innovation projects in which it has already attracted and managed more than €1M in state and European grants and subsidies, including R+D+i grants from the Government of Navarra. In addition, one of the milestones that undoubtedly create more value within the company and that has had a great relevance in this round of investment have been the negotiations that are currently being developed in contact with several multinationals to bring to market and start marketing their first products.

In this short but productive time, the company has consolidated its activity by creating a solid and highly qualified team of nine people, all of them with university degrees and several master's degrees, and which is growing rapidly. Of the current staff, around 80% are women in STEM fields, including the CEO of the company.The company has a strong focus on Biomedical Engineering and Industrial Design. Being a knowledge-oriented company, combining technological development and scientific research to produce innovation in the health sector.

Ysium also has a very powerful ecosystem with an Advisory Board and a Network of Experts with more than 15 members of recognized prestige that continues to grow. It has also signed collaboration agreements with research centers and leading universities such as Navarrabiomed and the Navarra Health Service, the Clínica Universidad de Navarra and the Universidad Francisco Marroquín, among others, and has received several awards for innovation and entrepreneurship, including the Navarra 2023 Industry Award in Health Technologies, granted by the Government of Navarra and Navarra Health Cluster (NHC).

To carry out this process, Ysium Medical has relied on the advice and experience of the renowned law firm specialized in this type of M&A operations and investment rounds, Lawesome.